

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

Adverse Events	Placebo (N=86)	Xanomeline High Dose (N=84)	Xanomeline Low Dose (N=84)
ABDOMINAL DISCOMFORT	0	1	0
ABDOMINAL PAIN	1	2	3
ACROCHORDON EXCISION	0	1	0
ACTINIC KERATOSIS	0	1	0
AGITATION	2	1	2
ALCOHOL USE	0	1	0
ALLERGIC GRANULOMATOUS ANGIITIS	0	1	0
ALOPECIA	1	0	0
AMNESIA	0	2	0
ANXIETY	2	0	4
APPLICATION SITE BLEEDING	0	0	1
APPLICATION SITE DERMATITIS	9	12	15
MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term.			

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

Adverse Events	Placebo (N=86)	Xanomeline High Dose (N=84)	Xanomeline Low Dose (N=84)
APPLICATION SITE DESQUAMATION	0	0	1
APPLICATION SITE DISCHARGE	0	1	0
APPLICATION SITE DISCOLOURATION	0	0	1
APPLICATION SITE ERYTHEMA	3	23	20
APPLICATION SITE INDURATION	1	0	0
APPLICATION SITE IRRITATION	7	16	18
APPLICATION SITE PAIN	0	2	0
APPLICATION SITE PERSPIRATION	0	3	0
APPLICATION SITE PRURITUS	10	35	33
APPLICATION SITE REACTION	2	1	0
APPLICATION SITE SWELLING	0	3	1
APPLICATION SITE URTICARIA	0	1	2
MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term.			

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

Adverse Events	Placebo (N=86)	Xanomeline High Dose (N=84)	Xanomeline Low Dose (N=84)
APPLICATION SITE VESICLES	2	6	5
APPLICATION SITE WARMTH	0	0	2
ARTHRALGIA	1	1	4
ARTHRITIS	2	1	0
ASTHENIA	2	1	0
ATRIAL FIBRILLATION	1	5	1
ATRIAL FLUTTER	0	2	1
ATRIAL HYPERTROPHY	2	0	0
ATRIOVENTRICULAR BLOCK FIRST DEGREE	1	0	1
ATRIOVENTRICULAR BLOCK SECOND DEGREE	2	4	0
BACK PAIN	2	4	1
BALANCE DISORDER	0	0	3
MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term.			

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

Adverse Events	Placebo (N=86)	Xanomeline High Dose (N=84)	Xanomeline Low Dose (N=84)
BENIGN PROSTATIC HYPERPLASIA	2	1	0
BIOPSY	0	1	0
BIOPSY PROSTATE	0	1	0
BLISTER	0	2	8
BLOOD ALKALINE PHOSPHATASE INCREASED	1	0	0
BLOOD CHOLESTEROL INCREASED	0	1	0
BLOOD CREATINE PHOSPHOKINASE INCREASED	2	0	0
BLOOD GLUCOSE INCREASED	0	2	1
BLOOD URINE PRESENT	1	0	0
BODY TEMPERATURE INCREASED	0	0	1
BRADYCARDIA	4	0	0
BRONCHITIS	1	0	0
MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term.			

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

Adverse Events	Placebo (N=86)	Xanomeline High Dose (N=84)	Xanomeline Low Dose (N=84)
BUNDLE BRANCH BLOCK LEFT	1	0	0
BUNDLE BRANCH BLOCK RIGHT	2	0	1
MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term.			

Dataset: ADAE | Cutoff: 01JAN2023